Teva's turnaround is real -- and may not be over.
Zacks Investment Research on MSN
Teva stock up more than 100% in a year: Time to buy, hold or sell?
Teva Pharmaceutical Industries Limited’s TEVA stock has risen 102.8% in the past year, fueled by strong revenue and earnings ...
Teva Pharmaceutical Industries (NYSE: TEVA) will unveil its first-quarter results this Wednesday, April 29. Many Teva ...
It's no longer a secret that the Teva Pharmaceutical Industries (NYSE: TEVA) of the past is no more. The Israel-based company ...
Teva Pharmaceuticals has joined other drug makers in filing a lawsuit against the Department of Health and Human Services for the drug-pricing provisions of the Inflation Reduction Act. Teva filed the ...
Teva Pharmaceuticals will stop shipping 36 discounted drugs to contract pharmacies July 5 because of its concerns of a diluted 340B program, according to a letter acquired by 340B Health. The New ...
New analysis from the IMPACT-TD Registry confirms tardive dyskinesia (TD) causes a significant burden for most individuals with concomitant mood ...
The polymyositis market is witnessing notable growth driven by the increasing prevalence of this autoimmune disease, particularly among older adults. Polymyositis leads to muscle inflammation and ...
Corcept Therapeutics Inc. will continue litigating state-law antitrust claims that it harmed competition in the market the cortisol-lowering drug Korlym, after a federal judge ruled that a rival’s ...
The head of the world's largest generic drugs company is to step down, less than two years after he took on the job in an effort to turn round the company. Teva, based in Israel, said on Wednesday ...
Drugmaker Teva Pharmaceuticals agreed to pay $225 million in criminal fines over five years to resolve charges related to price fixing three medications, including a generic cholesterol drug that it ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results